Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Loxo Oncology, Inc.
Scientific Title
A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC